Biotech Movers: Pacific Biosciences Falls After Net Loss Spikes

Shares of Pacific Biosciences of California (PACB)   were down nearly 17% to $4.30 in premarket trading on Thursday. The Menlo Park, Calif.-based firm on Wednesday reported a first-quarter net loss of $23.9 million, versus $19.4 million in the same period last year. Product and service revenue rose 60% to $24.9 million.

Shares of Alexion Pharmaceuticals (ALXN) were up 3.2% to $124.60. The New Haven, Conn.-based firm on Thursday reported first-quarter non-GAAP diluted earnings per share of $1.38, compared to $0.99 in the year-ago period. Revenue was $870 million, up 24% year-over-year.

The company said revenue for the first quarter included a benefit of $29 million from a change in revenue recognition in 2017 for certain non-U.S. markets. Not counting the benefit of this accounting change, revenue was  $841 million, representing a  20% rise from the year-ago period.

For full-year 2017, Alexion raised its GAAP EPS guidance to $2.80 to $3.20 from the previous range of $2.55 to $3.05, and non-GAAP EPS guidance to $5.10 to $5.30 from the prior range of $5.00 to $5.25. The company reaffirmed its revenue guidance of $3.4 billion to $3.5 billion.

Other biotech stock movers include Arena Pharmaceuticals (ARNA) , up 4.3% to $1.45.

More from Health

How to Get a Medical Marijuana Card

How to Get a Medical Marijuana Card

How To Get Rid of Fleas In Your House And More

How To Get Rid of Fleas In Your House And More

Sprout CEO: Don't Call Her Drug the Female Viagra

Sprout CEO: Don't Call Her Drug the Female Viagra

Can Legal Cannabis Help Slow the Opioid Drug Epidemic in the U.S.?

Can Legal Cannabis Help Slow the Opioid Drug Epidemic in the U.S.?

How to Invest in Cannabis - In Its Many Forms

How to Invest in Cannabis - In Its Many Forms